全文获取类型
收费全文 | 212篇 |
免费 | 28篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 13篇 |
基础医学 | 26篇 |
口腔科学 | 3篇 |
临床医学 | 25篇 |
内科学 | 35篇 |
皮肤病学 | 6篇 |
神经病学 | 9篇 |
特种医学 | 51篇 |
外科学 | 18篇 |
综合类 | 5篇 |
预防医学 | 15篇 |
眼科学 | 1篇 |
药学 | 14篇 |
1篇 | |
中国医学 | 12篇 |
肿瘤学 | 8篇 |
出版年
2023年 | 1篇 |
2022年 | 8篇 |
2021年 | 8篇 |
2020年 | 6篇 |
2019年 | 4篇 |
2018年 | 5篇 |
2017年 | 3篇 |
2016年 | 3篇 |
2015年 | 8篇 |
2014年 | 5篇 |
2013年 | 9篇 |
2012年 | 2篇 |
2011年 | 4篇 |
2010年 | 7篇 |
2009年 | 8篇 |
2008年 | 3篇 |
2007年 | 3篇 |
2006年 | 1篇 |
2005年 | 3篇 |
2004年 | 2篇 |
2003年 | 4篇 |
2002年 | 8篇 |
2001年 | 2篇 |
2000年 | 3篇 |
1999年 | 1篇 |
1998年 | 17篇 |
1997年 | 9篇 |
1996年 | 9篇 |
1995年 | 13篇 |
1994年 | 10篇 |
1993年 | 7篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1990年 | 5篇 |
1989年 | 2篇 |
1988年 | 6篇 |
1987年 | 10篇 |
1986年 | 4篇 |
1985年 | 8篇 |
1984年 | 11篇 |
1983年 | 1篇 |
1982年 | 4篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1976年 | 4篇 |
1962年 | 1篇 |
排序方式: 共有242条查询结果,搜索用时 15 毫秒
71.
72.
73.
74.
Exchange transfusion the hard way: massive hemolysis following transplantation of bone marrow with minor ABO incompatibility 总被引:2,自引:0,他引:2
BACKGROUND: Bone marrow transplantation using donors with minor ABO incompatibility may result in the rapid production of donor-derived red cell isohemagglutinins, causing hemolysis of recipient red cells. CASE REPORT: The transplant of sibling-donor marrow with minor ABO incompatibility (group O donor marrow to group A recipient), using FK- 506 as an immunosuppressant to prevent graft-versus-host disease, is reported. Following early myeloid engraftment, the recipient developed hemolysis of her entire A red cell population between Day 8 and Day 11. This brisk hemolytic anemia was due to rapid donor lymphoid engraftment that resulted in the explosive production of donor-derived anti-A. CONCLUSION: Patients undergoing the transplantation of marrow from donors with minor ABO incompatibility in which the donor cells can produce isohemagglutinins against the recipient's red cells must be kept under vigilant observation for the possible development of severe hemolysis, particularly in the setting of profound T-cell suppression without B-cell suppression. 相似文献
75.
E Quebe-Fehling PhD R Brambilla PhD CL Bromly RGN K Fishwick RGN EH Walters MD FRCP FRCCP DJ Hendrick MD FRCP 《International journal of clinical practice》1996,50(8):446-449
SUMMARY The duration of action of formoterol inhaled as a dry powder formulation is compared with placebo and a reference treatment of salbutamol dry powder in patients with bronchial asthma. This single-centre, double-blind, cross-over study recruited 23 outpatients with clinically stable asthma. These patients were treated with 12μg formoterol, 400μg salbutamol or placebo in a randomly allocated sequence, with at least 2 days between treatments. Forced expiratory volume in 1s of expiration (FEV1) was measured at specified time points from 15 min to 15 hours post-treatment. Formoterol produced significantly higher values of FEV1 at the primary endpoint of 12 hours compared with placebo and salbutamol. No differences between FEV1 values were seen for the active treatments of formoterol and salbutamol for the first 5 hours post-inhalation. Formoterol was significantly superior to placebo at all time points, whereas salbutamol was significantly superior to placebo for the first 5 hours.This study demonstrates that formoterol, when given as a dry powder inhalation, has a significantly longer duration of acute bronchodilator action than 400μg salbutamol inhaled as a dry powder. The duration of action of formoterol of at least 12 hours seen in this study is at least as long as that reported following administration from a metered dose inhaler (MDI) at the same dose level. The study also demonstrates that 12μg formoterol dry powder is well tolerated by patients. 相似文献
76.
目的:观察糖基化终产物(advanced glycation end products,AGEs)对人视网膜色素上皮细胞增殖的影响,以及川芎嗪对AGEs诱导的人视网膜色素上皮细胞增殖的拮抗作用。方法:实验于2003-09/2004-07在中南大学湘雅二医院中心实验室完成。①实验分组:原代培养人视网膜色素上皮细胞,第3 ̄8代用于实验,设空白对照组,DMEM培养基中不加入任何药物;AGEs对照物组,培养液中含100mg/L的AGEs对照物;AGEs组,培养液中含10,50,100,200,400mg/L的AGEs,分别干预视网膜色素上皮细胞24h及48h。②实验操作:川芎嗪干预实验:也设空白对照组;AGEs对照物组;AGEs组,培养液中含100mg/L的AGEs;AGEs 川芎嗪组,培养液中加入10,20,40,80,160,320,640mg/L川芎嗪30min后加入100mg/L的AGEs,分别干预视网膜色素上皮细胞24h。③实验评估:MTT微量酶比色法检测视网膜色素上皮细胞增殖情况。结果:①视网膜色素上皮细胞增殖情况:不同浓度AGEs组细胞增殖率均高于对照物组(P<0.01),100mg/LAGEs组增殖率(24,48h分别为39.45%,31.97%)高于其他组(P<0.01),48h与24h结果一致。②川芎嗪的抑制效应:与AGEs组比较,10,20,40,80,160mg/L川芎嗪对AGEs诱导的视网膜色素上皮细胞增殖无抑制作用(P>0.05),320及640mg/L川芎嗪有抑制作用,其抑制率为8.96%,15.08%(P<0.01)。结论:①AGEs可诱导人视网膜色素上皮细胞增殖。②低浓度川芎嗪对AGEs诱导的人视网膜色素上皮细胞增殖无抑制作用,高浓度川芎嗪具有抑制作用。 相似文献
77.
Shaodong Chen Manting Lin Xiao Zhao Fan Lu YujieWang Shulei Li BinYan Haihong Zhou 《Journal of traditional Chinese medicine》2014,(1):96-99
OBJECTIVE: To investigate how Chaiyuwendan de- coction(CWD) affects endocannabinoid levels in the adipose tissue of depressed rats. METHODS: Twenty-four male Sprague-Dawley rats were randomly divided into four groups with six rats in each. One group was randomly selected as the control group. The remaining three groups were subjected to chronic stress to induce depression. Groups were randomly assigned as a model group, CWD group, and amitriptyline group. CWD was giv- en to the CWD group once a day from the second day of modeling. The amitriptyline group was ad- ministered amitriptyline intragastrically(10 mg/kg) once a day. After treatment for 21 days, body weight and fat weight were measured and the lev- els of N-arachidonoylethanolamine(AEA), 2-arachi- donoylglycerol(2-AG), and N-palmitoylethanol- amine(PEA) in adipose tissue were determined with liquid chromatography-mass spectrometry.RESULTS: Compared with the control group, body weight, fat weight, AEA, and PEA were significantly lower, and 2-AG was higher, in the model group(P 0.05, P0.01). Compared with the model group, body weight, fat weight, the AEA, and PEA levels were significantly higher, and 2-AG level was signifi- cantly lower in the CWD group(P0.05). However, the levels did not differ significantly between the CWD group and the amitriptyline group. CONCLUSION: CWD could regulate the levels of AEA, 2-AG, and PEA in rats with depression induced by chronic stress. 相似文献
78.
Intrahepatic cholestasis, or impairment of bile flow, is an important manifestation of inherited and acquired liver disease. In recent years, human genetic and molecular studies have identified several genes, the disruption of which results in cholestasis. ATP8B1 (FIC1), ABCB11 (BSEP), and ABCB4 (MDR3) are disrupted in forms of progressive familial intrahepatic cholestasis (PFIC) and related disorders. Mutations in BAAT, TJP2 (ZO‐2), and EPHX1 have been identified in patients with hypercholanemia. A CLDN1 mutation was recently reported in patients with ichthyosis, leukocyte vacuoles, alopecia and sclerosing cholangitis (ILVASC), and North American Indian childhood cirrhosis (NAIC) is associated with a missense mutation in CIRH1A. Alagille syndrome patients carry mutations in JAG1, and mutations in VPS33B have been identified in patients with arthrogryposis, renal dysfunction and cholestasis syndrome (ARC). Identification of these genes, and characterization of the proteins they encode, is enhancing our understanding of the biology of the enterohepatic circulation in health and disease. 相似文献
79.
Fumiko Nakamura Kentaro Kajino Tetsuhisa Kitamura Mohamud R Daya Marcus EH Ong Tasuku Matsuyama Tomoki Yamada Koichi Hayakawa Taro Irisawa Kazuhisa Yoshiya Kazuo Noguchi Tetsuro Nishimura Toshifumi Uejima Yoshiki Yagi Takeyuki Kiguchi Masafumi Kishimoto Makoto Matsuura Yasuyuki Hayashi Taku Sogabe Takaya Morooka Taku Iwami Takeshi Shimazu Yasuyuki Kuwagata 《Geriatrics & Gerontology International》2019,19(11):1088-1095
80.